A significant challenge in PCa clinical management is posed by the inability of the current diagnostic tests, such as serum Prostate-specific antigen (PSA) testing, digital rectal examination (DRE), to diagnose prostate cancer accurately and to discern between indolent and aggressive disease [3–6]. Here, KLK3 is linked to prostate cancer.